In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Courtney Granville, Director, Scientific Affairs, Drug Information Association, discusses issues that will be addressed at the upcoming FDA town hall.
Phase III KEYNOTE-564 Trial Data Show Keytruda Improves Survival in Renal Cell Carcinoma
January 29th 2024Trial shows Keytruda improved overall survival by 38% compared with placebo in in patients with renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy and resection of metastatic lesions.